dr. sequist discusses combination regimens in egfr nsclc
Published 6 years ago • 129 plays • Length 1:03Download video MP4
Download video MP3
Similar videos
-
0:55
dr. sequist discusses the efficacy of co-1686 for nsclc
-
1:05
dr. sequist on frontline egfr tki use in nsclc
-
0:58
dr. sequist distinguishes osimertinib from earlier nsclc tkis
-
1:39
dr. sequist on implications of the impower150 trial in advanced nonsquamous nsclc
-
1:11
dr. sequist on rationale for tatton trial in egfr-mutant lung cancer
-
0:49
dr. sequist discusses adverse events associated with co-1686
-
2:25
dr. sequist discusses the os analysis of lux-lung 3 and lux-lung 6
-
4:09
frontline afatinib in egfr-mutant nsclc
-
3:24
sequencing of therapies in egfr-mutant nsclc
-
1:15
lecia v. sequist on side effects from agents for resistant lung cancer
-
27:03
dr. lecia sequist (pt. 1): combining interests in science and practical issues in cancer care
-
0:53
dr. sequist on pembrolizumab monotherapy in nonsquamous nsclc
-
28:17
segment 1: egfr tkis in nsclc
-
1:34
dr. sequist discusses the impress trial
-
9:25
tatton: updated results for patients with egfr-mutant positive nsclc
-
1:42
dr. bazhenova on sequential use of immunotherapy and egfr tkis in lung cancer
-
5:15
metastatic nsclc: a look at the impower150 trial
-
5:08
the impower150 regimen
-
6:41
egfr-positive nsclc: treatment at progression